Summary
The serum levels of alpha-1-antichymotrypsin (ACT) were studied in 168 patients with various liver diseases and cancers in conjunction with other liver function tests, serum sialic acid, AFP and CEA. The ACT levels in acute viral hepatitis and chronic hepatitis were not significantly altered compared with the normal level (220 ± 40µg/ml), although the level was slightly increased or decreased temporarily during the acute phase of the former. In liver cirrhosis, the mean level was significantly lower than the normal in spite of the absence of signs of hepatic decompensation (168 ± 51 Μg/ml, p<0.001). In contrast to cirrhosis, the levels were increased to various extents in 65 % of cases with hepatoma, in spite of the association of liver cirrhosis in the majority of them. Much higher levels were observed in all cases of metastatic liver cancers and cancers of the pancreas and the biliary tract. The elevations were observed even in cases without the increase of AFP or CEA. Both in cirrhosis and cancers, ACT levels were not correlated with any of serum bilirubin and serum enzyme activities, but were positively correlated with the levels of plasma fibrinogen and serum sialic acid. The measurement of serum ACT level can be taken advantage of for the diagnosis and monitoring of liver cirrhosis and liver cancers, particularly of hepatoma without AFP elevation.
Similar content being viewed by others
References
Sarcoine EJ: Synthesis of alpha-1-acid glycoprotein by the isolated perfused rat liver. Arch Biochem Biophys 100: 516, 1963
Krauss S, et al: Synthesis of serum haptoglobin by isolated perfused rat liver. Biochim Biophys Acta 90: 301, 1964
Bhan AK, et al: Liver in alpha-1-antitrypsin deficiency: Morphological observations and in vitro synthesis of alpha-1-antitrypsin. Pediat Res 10: 35, 1976
Ohara H, et al: Clinical and biochemical studies of serum haptoglobin. I. Clinical significances of serum haptoglobin determination. Saishin Igaku 24: 2174, 1969
Kindmark CO, et al: Sequential changes of the plasma protein pattern in inoculated hepatitis. Scand J Clin Lab Invest 29: Suppl 124: 105, 1972
Skrede S, et al: Serum proteins in diseases of the liver. Scand J Clin Lab Invest 35: 399, 1975
Mihas AA: Serum alpha-1-antitrypsin in alcoholic hepatitis. Digestion 17: 275, 1978
Carlson J, et al: Alpha-1-antitrypsin and other acute phase reactants in liver disease. Acta Med Scand 207: 79, 1980
Aronsen KF, et al: Sequential changes of plasma proteins after surgical trauma. Scand J Clin Lab Invest 29: Suppl 124: 127, 1972
Kelly VL, et al: The assessment of antichymotrypsin in cancer monitoring. Biomedicine 28: 209, 1978
Nakazaki H, et al: Clinical significance of serum DNA binding protein (64 DP) in evaluating malignant diseases. Gann 72: 280, 1981
Katsunuma T, et al: Purification of serum DNA binding protein (64 DP) with molecular weight of 64,000 and its diagnostic significance in malignant diseases. Biochem Biophys Res Comm 93: 552, 1980
Matsumoto M, et al: Enhancement by alphal-antichymotrypsin of the antibody response in vivo. Biochem Biophys Res Comm 100: 478, 1981
Warren L: The thiobarbituric acid assay of sialic acids. J Biol Chem 234: 1971, 1959
Sharp HL, et al: Cirrhosis associated with alpha-1antitrypsin deficiency: A previously unrecognized inherited disorder. J Lab Clin Med 73: 934, 1969
Berg NO, et al: Liver disease in adult with alpha-1-antitrypsin deficiency. N Eng J Med 287: 1264, 1972
Morse JO: Alpha-1-antitrypsin deficiency (First of two parts). N EngJ Med 299: 1045, 1978
Morse JO: Alpha-1-antitrypsin deficiency (Second of two parts). N Eng J Med 299: 1099, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsuzaki, S., Iwamura, K., Itakura, M. et al. A clinical evaluation of serum alpha-1-antichymotrypsin levels in liver disease and cancers. Gastroenterol Jpn 16, 582–591 (1981). https://doi.org/10.1007/BF02813793
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02813793